Lundbeck

The impact of brain disorders is escalating. It is estimated that brain disorders directly affect half the world’s population, and the effects are felt throughout society. Every day we go to work to address high unmet medical needs for people living with brain disorders. Patients who have few or no treatments available. Through cutting-edge science and strong partnerships, we develop and market some of the world’s leading treatments, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. Our most important contribution is easing the burden of the millions of people living with brain disorders. Whether it is migraine, depression, or other brain disorders, patients, their carers, and society as a whole depend on us. At Lundbeck, we are - Advancing brain health. Transforming lives. #AdvancingBrainHealth #FocusedInnovator

En Lundbeck, estamos dedicados a transformar la ciencia en soluciones, trabajando cada día para aliviar la carga de los trastornos cerebrales y marcar una diferencia real en la vida de las personas. *Consulte a su médico

👩🔬 Celebrating Women in Science at Lundbeck On this International Day of Women and Girls in Science, we proudly celebrate the achievements of women who are shaping the future of brain research.   Meet Beatriz Cruz Luzon, our 2024 Brain Battle winner and PhD student, Diahann Atacho, Global Project Manager in Research and Development (R&D), and Director Julie Klint, Molecular Discovery & Enabling Tech. They are just a few of the inspiring women at Lundbeck who are driving scientific progress and innovation.   In this short video, they share their passion for science, their perspectives on diversity and inclusion, and what it takes to create more opportunities for women in Science, Technology, Engineering, and Mathematics (STEM). Share your thoughts in the comments below and let's inspire each other! 💡👩🔬   #WomenInSTEM #DiversityEquityAndInclusion #STEM #GenderEquality

🔍 New Data: The costs of brain diseases in Denmark A new Brain Report from Aarhus University, published in The Lancet Regional Health Europe, sheds light on the extent and socio-economic costs of brain diseases in Denmark. Key findings reveal the critical need for more research to improve prevention and treatment: 🧠 Widespread prevalence: More than 1/3 of Danes live with a brain disease, diagnosed through hospital visits or medication use. ⚠️ Higher mortality risk: The mortality rate for people with brain diseases is, on average, 5x higher within a year compared to those without. 💰 Economic burden: Brain diseases cost Denmark nearly 230 billion DKK annually in both direct and indirect expenses. The report also provides cost data for patients and their families. 🔗 Find the full report via the link in the comments. 

🌿 Creating a sustainable future begins with taking responsibility today. At Lundbeck, we're proud to be recognized on CDP’s Climate Change A List, which honors companies leading the way in environmental accountability and action. We believe that being transparent about our environmental impact is the first step toward meaningful change. By following best practices and setting and achieving ambitious and meaningful goals, and have committed to set near- and long-term company-wide emission reductions with science-based net-zero guidance from the Science Based Targets initiative (SBTi). This year is a milestone for us, as we published our first integrated Annual Report, featuring extensive sustainability disclosures aligned with the European Corporate Sustainability Reporting Directive (CSRD). While the EU ESG reporting requirements are not perfect, the updated regulations drive much-needed transparency and comparability in ESG reporting. See the Annual Report published this week and read full details on progress and challenges on Lundbeck’s transition path: https://lnkd.in/dHNrky_y The CDP scoring evaluates companies on their disclosure practices, awareness, and management of environmental risks, as well as their adoption of best practices, including setting ambitious targets each year. Want to learn more? 🔗 CDP Scores and A Lists https://lnkd.in/deA2vmsk 🔗Ludbeck's climate action https://lnkd.in/eeu_dTnj Dorte Vigsø

📢 What an extraordinary year for Lundbeck! 🎉 We’re proud to share our full-year 2024 results — a year of extraordinary achievements as we mark the first year of our #FocusedInnovator strategy. What we are proud of: ❤️ +7 million full-year patients reached globally: Making a real difference for our patients is the reason we come to work every day. In 2024, we added an increasing emphasis on neuro-rare disorders, as we continued developing new treatments in neuroscience. Our most important contribution is easing the burden of the millions of people living with brain disorders.   💡 Innovating for our patients: Our R&D pipeline is transformed. We anticipate having four phase III assets by 2026, including one from our recent acquisition of Longboard Pharmaceuticals. We expect at least two impactful product launches by 2029. 🔑 Record-breaking revenue: DKK 22 billion, driven by the accelerated growth of our strategic brands across all regions. This success allows us to fund innovation —and continue to address critical unmet medical needs. Explore more highlights below and on our website 👇  https://lnkd.in/d8dXbaTw

🧠 Shaping the future of brain health Our CEO, Charl van Zyl, joins the EMJ Gold Podcast to share Lundbeck's vision for innovation, sustainability, and how we constantly strive to create a lasting impact for patients . 💭 From the advancements in neuroscience to the importance of creating societal value—this episode is packed with insights. 🎧 Tune in to the full conversation – link in the comments 👇. #Lundbeck #BrainHealth #FocusedInnovator

San Francisco, here we come! Lundbeck is gearing up for the 43rd Annual J.P. Morgan Healthcare Conference. It’s an exciting opportunity to meet with the investor community, exchange ideas with industry leaders, and explore the trends shaping the future of neuroscience. Don’t miss Charl’s company presentation on January 13th, where we’ll showcase advancements in our #FocusedInnovator strategy. For further information, please refer to our website: https://lnkd.in/dtKnn3a9 We can’t wait to connect! #JPM2025 Charl van Zyl, Joerg Hornstein, Maria Alfaiate, Johan Luthman, Palle Holm Olesen, Jens Hoeyer

🌟Dreaming about an industrial PhD in Neuroscience? This is your moment to shine! 🧪👏 Join the Lundbeck Brain Battle 🧠⚡ and take the first step toward your dream career! The competition is open to MSc students and recent graduates who aspire to earn a PhD in neuroscience. What’s at stake? The winner will be awarded a fully-funded industrial PhD in neuroscience at Lundbeck, in collaboration with a Danish university. Last year, Beatriz Cruz Luzon took the leap after spotting this post on LinkedIn. Today, she’s thriving as a Brain Battle winner and shared her inspiring journey with you: "The Brain Battle experience was not only enriching but also very fun! As a shortlisted candidate, I attended workshops with a coach who taught us how to present our science ideas creatively and engagingly. We worked on storytelling and presentation skills— and getting on stage was a real step outside my comfort zone. Even if I hadn’t won, I knew I’d gained valuable skills to carry forward in my career." What has surprised you the most since you joined Lundbeck? "In just three months, I’ve met and collaborated with scientists across diverse fields, learning new techniques and perspectives. My scientific world has expanded and feels more vibrant and dynamic—it’s been truly refreshing." 💡 Beatriz’s Top Tips for Future Brain Battle Participants: 1️⃣ Let your personality shine!  "Incorporate your life experiences and unique qualities into your presentation. Be authentic—it’s not just about the science; it’s about the whole you." 2️⃣ Focus on storytelling!  "Your project doesn’t have to be perfect. I shared a project with negative results, but I turned it into a story about what I learned. It’s the narrative that matters." 🌟 Tempted to apply? Don’t wait—the deadline is January 31, 2025! Learn more and submit your application today: https://lnkd.in/dtU9TWWM

Axonis Therapeutics wins Lundbeck’s Golden Ticket 2024 at BioLabs! 🎉 We’re excited to share that Lundbeck has joined forces with BioLabs, a global leader in biotech incubation, to support the development of treatments for patients suffering from brain disorders. Driven by our mission to make a meaningful impact on patients, people, and society, we are proud to sponsor one of the Golden Tickets at BioLabs as part of our commitment to innovation in brain health. This year, we’re proud to award a Golden Ticket to Axonis Therapeutics, granting them a year of access to BioLabs’ Boston site. This includes essential infrastructure, equipment, and resources to further develop their research. Join us in congratulating the Axonis Therapeutics team! 🙌